Skip to main content

Advertisement

Table 3 Duration and discontinuation of PEG-IFN-alfa/ribavirin therapy in insured patients receiving treatment for chronic HCV infection

From: Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study

Patient group   Duration of PEG-IFN-alfa/ribavirin therapy (days) Discontinue before 12 wk Discontinue before 24 wk Discontinue before 48 wk
  No. of patients Mean (SD) Median n (%) n (%) n (%)
All 1,269 214.8 (113.8) 195 180 (14.2) 416 (32.8) 897 (70.7)
Patients with known GT 238 223.1 (115.3) 211 32 (13.4) 79 (33.2) 165 (69.3)
GT 2/3 45 161.3 (60.4) 168 4 (8.9) 18 (40.0) 44 (97.8)
GT 1/4/6 193 237.5 (120.2) 282 28 (14.5) 61 (31.6) 121 (62.7)
Patients treated >28 weeksa 618 315.6 (57.1) 339 246 (39.8)
  1. GT, genotype; HCV, hepatitis C virus; PEG-IFN-alfa, pegylated interferon alpha.
  2. aPresumed to have predominately GT-1 infection.